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Background: Nuclear factor of activated T-cells (NFAT) is a general name applied to a family of transcription factors
shown to be important in immune response. One or more members of the NFAT family are expressed in most cells
of the immune system. NFAT1 is considered to involve in the development of cardiac, skeletal muscle, nervous
systems, and tumorigenesis.
Methods: In the current study, we analyzed MEKK1 expression in 159 surgically resection non-small cell lung cancer
patient’s samples by immunohistochemistry and determined its role in SK-EMS-1 cells via RNAi experiment.
Results: The abilities of invasion, motility, and adhesion of SK-EMS-1 cells were detected by transwell assay, wound
healing assay and adhesion assay, respectively. The result showed NFAT1 was highly expressed in lung tumor
tissues instead of adjacent lung tissues (54.1% vs 8.8%, p < 0.05); its overexpression was positively correlated with
lymph node metastasis (p < 0.05). Depleting its expression in SK-EMS-1 cells can inhibit its invasion and migration
abilities significantly (p < 0.05); and also can reduce proliferation of lung cancer cells (p < 0.05).
Conclusion: Our study showed NFAT1 plays an important role in origination, invasion and metastasis of non-small
lung cancer cells; its underlying action mechanism needs further study.
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Nuclear factor of activated T cells (NFAT) was initially
identified as an inducible nuclear factor that could bind the
interleukin-2 (IL-2) promoter in activated T cells [1]. When
all of the proteins of the NFAT family had been isolated
and molecularly characterized, it became clear that their
expression was not limited to T cells. At least one NFAT
family member is expressed by almost every cell type that
has been examined, including other cells of the immune
system and non-immune cells [2-5]. The NFAT family con-
sists of five members: NFAT1 (also known as NFATp or
NFATc2), NFAT2 (also known as NFATc or NFATc1),
NFAT3 (also known as NFATc4), NFAT4 (also known as
NFATx or NFATc3) and NFAT5, all are calcium responsive
and are regulated by the calcium/calcineurin signaling
pathway [3,6]. The terms NFATp and NFATc were origin-
ally used to describe DNA-binding activities present in cel-
lular extracts; hence, more than one NFAT family protein* Correspondence: jifu.liu@yahoo.cn
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reproduction in any medium, provided the ormay have been present in the original NFATp (preexisting)
and NFATc (cytoplasmic) preparations [7].
In resting cells, NFATs are phosphorylated at a cluster of
serine residues located in the regulatory domain, effectively
masking a nuclear localization signal, thereby retaining
NFAT in an inactive conformation in the cytoplasm [2,8],
Upon stimulation with agonists that elicit an increase in
intracellular calcium, NFATs are dephosphorylated by the
phosphatase calcineurin and translocate to the nucleus.
Here they are transcriptionally active by binding to the
promoter regions of target genes [9,10]. Classical NFATs
typically interact with other transcription factors such as
AP-1 [11,12] and GATA4 [13] to activate transcription.
Adjacent NFAT and AP-1 binding sites are present in the
promoter region of inducible genes including IL-2 and
cyclooxygenase-2 (COX-2) [11,14]. Recent studies have
showed the expression of NFAT in human cancers, such
as breast Cancer [15] and human metastatic melanoma
cell lines [16], however, the expression of NFAT in non-
small-cell lung cancer (NSCLC) remain undefined. There-
fore, the aim of this study was to investigate its role inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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firstly analyzed the NFAT1’s expression in lung cancer tis-
sues, and further constructed eukaryotic expression system
and RNA interference was introduced to get stable expres-
sion lung cancer cell lines with or without NFAT1 to dis-
cuss its effect on lung cancer cell growth and invasion.
Materials and methods
Patients and samples
The paraffin-embedded tissue samples from 159 patients
with non-small cell carcinoma diagnosed between 2008
and 2011 were obtained from the department of Thoracic
Surgery, General Hospital of Beijing Military Region. All
the tissue samples were obtained after resectional oper-
ation of the lung cancer. Information of age, gender,
histological type, differentiation grade, and lymph node
metastasis of lung adenocarcinomas were obtained from
the Surgical Pathology Files in the hospitals. The clinico-
pathological diagnosis on the tumor status was evaluated
by the clinical pathologists in the hospital.
Immunohistochemistry
Standard indirect immunoperoxidase procedures were
used for immunohistochemistry. In brief, the sections of
159 patients were incubated in NFAT1 primary mono-
clonal antibody (43-γ, Santa Cruz) (1:200) overnight at
4°C. Control sections were incubated with PBS instead.
After washing four times with PBS, the sections were in-
cubated in biotinylated anti-rabbit IgG (1:1,000) for 1 h,
followed by rinsing and incubation with avidin–biotin–
peroxidase complex for 30 min. The peroxidase reaction
was developed using 3, 3-diaminobenzidine for 6 min.
The immunostained slides were evaluated independently
by two pathologists. The brown staining in cytoplasm
was defined as the positive signal.
Cell Lines and specimens
The human lung fibroblasts (HLF-1), human non-small
cell lung cancer cell lines A549 and SK-MES-1 were
obtained from ATCC(Massachusetts, USA), they were
cultured in RPMI-1640 media supplemented with 10%
fetal calf serum, penicillin (100 U/mL) and streptomycin
(100 ug/mL) (Gibco BRL), and incubated at 37°C in a
humidified air atmosphere containing 5% CO2. The cells
were harvested with three time washing.Figure 1 Immunohistochemistry result of NFAT1 in lung cancers and adReal Time PCR
Total RNA was extracted with Trizol (Invitrogen). RT-
PCR was performed with 1 μg of total RNA after the
first chain of cDNA synthesized with a condition of an
initial denaturation at 95°C, denature at 94°C for 30 s,
annealing at 59°C for 45 s and elongation at 72°C for
1 min for 30 cycles. The primers are, NFAT-1 (137 bp):
forward: TTCCTACCCCACAGTCATTC and reversed:
AGGTCTGGTCCAAGTTCTG; GAPDH (590 bp): for-
ward: ACCCAGAAGACTGTGGATGG and reversed:
AGGGGTCTACATGGCAACTG. The primers for both
NFAT1 and GAPDH were used in the same reaction
during the PCR amplification. qRT-PCR carried out
using SYBR Green master mix with 7900HT Sequence
Detection System from Applied Biosystems (USA). The
mRNA expressions of NFAT-1 were compared among
HLF-1, A549 and SK-MES-1.
NFAT1-siRNA and cell transfection
Small interfering RNAs (siRNAs) targeting NFAT1
(U43342 in GenBank) were chemically synthesized
(GenePharma Co.). The target sequences for effective
silencing of NFAT1 gene were selected from 1,620 to
1,638nt (siRNA1, sense sequence: 5′CCUUCAGACCC
AAUGUUAUTT 3′; antisense: 5′AUAACAUUGGGU
CUGAAGGTT3′), 1,686–1,704nt (siRNA2, sense se-
quence: 5′GCUGCAGCGUUCUGUCAAUTT 3′, anti-
sense: 5′ AUUGACAGAACGCUGCAGCTT 3′); and
2,898–2,916nt (siRNA3, sense sequence: 5′ CCGGG
UGUUUCAACUAGAATT 3′; antisense: 5′ UU CUAG
UUGAAACACCCGGAG 3′). The over-hanged UU in
the siRNAs was replaced by dTdT for enhancement of
its stability in cells. A total amount of 1.6-μg siRNA per
well was used to transfect the SK-MES-1 cells using
LipofectAMINE 2000 (Invitrogen) according to the manu-
facturer’s protocol. A non-specific gene sequence was used
as a negative control. The GFP-conjugated control siRNA
was used to evaluate the transfection efficiency. RT-PCR
and Western blot were used to analyze NFAT1 mRNA and
protein level, respectively.
Western blotting
Total cellular protein was extracted using lysis buffer
[50 mM Tris–HCl (pH 7.4), 1 mM EDTA, 250 mM
NaCl, 1% Triton X-100, 5 mM MgCl2, 2 mM Na3VO4, andjacent tissues (200×). a, normal tissue (-); b, tumor tissue (-); c, NFAT1 (+).
Table 1 Expression of NFAT1 protein in 159 non-small
cell lung cancer patients
Parameters Case number P value
NFAT1 positive in lung cancer tissues 86(159)
NFAT1 positive in adjacent normal tissues 14(159) <0.01
Positive in lymph node metastasis 35(55) 0.027
Positive in non-lymph node metastasis 13(31)
Analyzed by Person’s chi-square test.
Figure 3 Expression of NFAT1 in SK-MES-1 cells. a, RT- PCR result
with or without siRNAs; b, Western blot with or without siRNA3.
GAPDH served as control.
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was measured using Bio-Rad protein assay. Equal amount
of protein was separated using 10% SDS-PAGE and
transferred to nitrocellulose membranes (Amersham).
The membranes were blocked with 5% skimmed milk
in PBS buffer and incubated overnight with primary
antibodies followed by horseradish peroxidase conju-
gated antibodies at room temperature. β-actin was
used as internal positive control. Primary antibodies
included NFAT1 (C-22) was purchased from Santa
Cruz. Signals were visualized using enhanced chemi-
luminescence system (Amersham).
Invasion assay
Invasion assay was performed using Boyden chamber
system (Neuro Probe) with a fibronectin-precoated
(0.5 mg/ml) polycarbonate membrane (8 μm pore size).
The lighter side of the polycarbonate membrane was
precoated with 250 μg/ml matrigel (BD). The bottomFigure 2 Expression of NFAT1 in A549, SK-MES-1 and HFL1 cell
lines. a, RT-PCR; b, western blotting.
Figure 4 Depletion of MEEK1 in SK-MES-1 cells. a Invasion of
untransfected cells, control-siRNA, and NFAT1-siRNA3 transfected
SK-MES-1 cells; b histogram comparison results.
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containing 2% BSA while the top chambers were filled
with 50-μl RPMI1640 serum-free medium containing
0.2% BSA. 5 × 104 cells per well were added to the top
chamber, followed by a 15 h incubation in 37°C, 5%
CO2 incubator. Three independent experiments were
performed with triplicate treatment. The cells were
fixed in methanol and stained with haematoxylin. The
top surface of the membrane was gently scrubbed
with a cotton bud, the cells migrated to the lower side
of the membrane was counted under the microscope
and the numbers of migrated cells were calculated as
average plus SD.Figure 5 Depletion of MEEK1 in SK-MES-1 cells. a, Wound healing resul
SK-MES-1 cells; b, Cell motility results.Adhesion assay
The same amounts of NFAT1-siRNA and control-siRNA
transfected and untransfected SK-MES-1 cells (3 × 104)
were plated onto the matrigel-precoated (50 μg/ml) 96-
well plate in triplicate. The cells were washed at 30, 60,
and 120 min to remove non-adherent cells. 0.2% BSA
precoated wells served as the negative control. After
washing, the adhered cells were measured with MTT
assay. The relative optical density (OD) was determined
at 570 nm using WELLSCAN MK3 ELISA (Labsystems,
Dragon, Finland) and a 450 nm reference filter. The OD
values reflected the proportion of cells in the matrigel
coated 96-well plate.t of untransfected cells, control-siRNA and NFAT1-siRNA3 transfected
Figure 6 The adhesion and proliferation test after transfected
siRNA3 targeting NFAT1 in SK-MES-1 cells. a. adhesion ability
test; b. proliferation ability test. *P < 0.05, **P < 0.01, compared
with control.
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Wound healing assay was conducted as previously de-
scribed. The distance of wound closure (compared with
control at 0 h) was measured in three-independent wound
sites per group. Relative cell motility was calculated as the
wound width at t = 0 h minus the wound width at t = 24 h,
as indicated. Values from at least three-independent exper-
iments were pooled and expressed as means ± SD.
Results
Expression of NFAT1 protein in lung adenocarcinomas
and its clinic-pathological significance
Of the 159 non-small cell carcinoma patients, the results
of immunohistochemistry demonstrated that the NFAT1
positive staining (Figure 1c) was noted in 86 samples
(54.1%) while only 14 positive cases in adjacent normal
lung tissues (8.8%), p < 0.01. These results suggested
NFAT1 is positively correlated with origination of lung
cancer. We further analyzed the relationship of the
NFAT1 positive staining with the progression and inva-
sion of the tumor. We observed that all the samples with
the lymph node metastasis were 63.6% positive (N = 55)
staining while 13 out of 31 cases of non-lymph node me-
tastasis (42.5%) were of positive staining, p = 0.027
(Table 1). All these results suggested that the NFAT1 ex-
pression was significantly associated with lymph node
metastasis in the observed non-small lung cancer pa-
tients (Table 1; P < 0.05). The NFAT1 staining did not
show significant difference among the patients of differ-
ent gender, age, tumor location, and tumor size (data
not shown; P > 0.05).
Expression of NFAT1 in lung cancer cell lines
To observe whether the NFAT1 expression is related to
lung cancer in vitro, we examined the NFAT1 mRNA
and protein levels in different lung cancer cell lines
(A549 and SK-MES-1), HLF-1 was used as negative con-
trol. The data showed that the NFAT1 mRNA level
remained highly abundant in both cell lines compared to
HLF-1 (Figure 2a). A Western blot analysis further con-
firmed the NFAT1 protein expression in a similar pattern
in the both observed lung cancer cell lines (Figure 2b).
Specific depletion of NFAT1 expression by NFAT1 siRNAs
To examine whether the highly expressed NFAT1 is the
cause for the strong invasive ability, we depleted NFAT1
using the RNA interference method in SK-MES-1 cells.
We selected and synthesized three siRNAs against
NFAT1. The efficiency of the selected siRNAs was exam-
ined by transfection in the SK-MES-1 cells. RT-PCR
analysis revealed that siRNA2 and siRNA3 have a signifi-
cant inhibitory effect on the endogenous NFAT1 expres-
sion while the siRNA1 showed relatively weaker effect
(Figure 3a). The effects of the selected siRNA3 werefurther confirmed by a western blot to prove it could
inhibit NFAT1 expression strongly on protein level
(Figure 3b). Based on these results, we determined to
use siRNA3 for the following experiments.
Effects of siRNA3 targeting NFAT1 on invasive, motive
and adhesive abilities and proliferation of SK-MES-1 cells
To study the role of NFAT1 on the cell invasion, motil-
ity, and adhesion, which are the major characteristics of
the metastasis, we used siRNA3, the most powerful one
we selected, to deplete the endogenous expression of
NFAT1 in the SK-MES-1 cells. All the assays were
performed after 48 hour transfection. In an invasion
assay, we calculated the number of cells that migrated to
the bottom side of the membrane on a chamber where
the cells were seeded (Figure 4). The data showed that
the wild type SK-MES-1 cells had more numbers of the
migrated cells with or without transfection of a control
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transfected into the cells, numbers of the migrated cells de-
creased dramatically (Figure 4b). These results suggested
that the depletion of NFAT1 significantly suppressed the
migration ability of SK-MES-1 cells.
To examine whether the depletion of NFAT1 has any
effect on the motive ability of the cells, we performed
a wound-healing experiment using SK-MES-1 cells
transfected with or without control-siRNA and siRNA3.
The data showed that the wild type SK-MES-1 cells had
no difference in the relative wound closure with or with-
out transfection of the control siRNA, but a significant
difference was observed for the cells transfected with or
without siRNA3 targeting NFAT1 (Figure 5) both in 15
and 24 h.
The highly expressed NFAT1 correlated to the lung
cancer metastasis in the tumor patients reminded us
to examine whether NFAT1 has an effect on cell adhe-
sion to ECM (extracellular matrix). For this purpose,
we performed a cell adhesive assay using siRNA3
targeting NFAT1 in the SK-MES-1 cells. The results
showed that the cells, when transfected with siRNA3,
obtained low adhesion ability, compared with the wild
type cells (Figure 6). The results were in consistence
during different times as we observed in 30, 60, and
120 min, respectively. These results indicated that
NFAT1 may help the tumor cells adhere to the ECM.
Taking together, our data suggest that NFAT1 exerts
its effects on metastasis by inhibiting invasion, migra-
tion, and adhesion in SK-MES-1 cells.
Discussion
Failure of treatment for non-small lung cancers is mainly
caused by metastasis and invasion of the tumor cells to
the neighboring organs. 80% of lung cancer patients
were diagnosed at advanced stage. To reveal the metas-
tasis mechanisms is important to help and improve the
success of this cancer. Till date, several factors and sig-
naling pathway have been identified in the regulation of
metastasis of lung cancer. However, it remains unclear
its detailed mechanisms. In this report, we observed that
NFAT1 was highly expressed in the lung cancer patients.
This is in consistence with the results observed in the
lung cancer cell lines. In the current study, we observed
that the expression of NFAT1 is closely related to occur-
rence of lung cancer in the 159 patients by IMC, and
more importantly, its overexpression was significantly
related with lymph node metastasis.
Gaudineau et al. [17] have conform NFAT1 is a tran-
scription factor that elicits breast carcinoma cells to be-
come invasive, contributing thus to formation of
metastasis. To demonstrate whether NFAT1 contributes
to metastasis of lung cancer, we depleted it in SK-MES-1
cells, which showed high level of NFAT1 expression andstrong invasive ability, and confirmed that NFAT1 plays
a major role in controlling the cell invasion, migration,
and motility. All of our results are in consistence,
suggesting targeting NFAT1 could be a strategy for the
development of lung tumor therapy.
NFAT1 initially was determined to transcriptionally
regulate cytokines during immune response. NFAT1 is
Ca2+-responsive and modulated by calcineurin. In the
nucleus, they are transcriptionally active and bind to
the promoter regions of a set of genes including TNF-α,
IL-2, IL-3, IL-4, IL-5, GM-CSF, and IFN-γ. When cells re-
turn to the quiescent state, NFATs are rephosphorylated
by kinases, such as protein kinase A and glycogen syn-
thase kinase-3β. As the most studied NFAT, NFAT1 has
been shown to elicit both breast cancer and colon carcin-
oma cell invasion via COX-2. Activation of NFAT1 can
also increase vascular smooth muscle cell motility. In the
current study, we confirm the importance of NFAT1’s in-
volvement in cell motility; we assume it derives from its
participation in PlGF-induced myelomonocytic cell re-
cruitment, and the NFAT1 expression was significantly
associated with differentiation, lymph node metastasis in
the observed non-small lung cancer patients.
In summary, tumor invasion requires both tumor cell
migration and degradation of local matrix barriers. Obvi-
ously, expression NFAT1 can enhance these abilities for
lung cancer cells. But its detailed action mechanisms
need further study.
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